John l. Higgins

John l. Higgins (chief executive) discloses dealings in 3 companies, chiefly Ligand Pharmaceuticals Inc, OmniAb, Inc. and BIO-TECHNE Corp. The record holds 48 filings, for trades running from 11 February 2016 to 28 September 2026.

Both buying and selling appear: 4 purchases worth €408k, against 5 sales worth €2.0M. On balance, insiders were net sellers of €1.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 18 share grants and 19 option exercises.

The median purchase comes to €64k. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days. After 4 purchases with a full 90-day history, the hit rate stands at 50% and the median 90-day move at -10.4%. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 30 September 2026: an option exercise, in BIO-TECHNE Corp. The last insider purchase was made public on 10 November 2025, 342 days ago. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.